|
Aridis Pharmaceuticals Inc (ARDS) |
|
Aridis Pharmaceuticals Inc
ARDS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Aridis Pharmaceuticals Inc growth rates, revenue grew
by 4.51 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 1321
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -2.27 %
Aridis Pharmaceuticals Inc net loss decreased from $-8 millions, to $0 millions in III. Quarter 2023,
• More on ARDS's Growth
|
|
Aridis Pharmaceuticals Inc realized a net loss in trailing twelve months.
Aridis Pharmaceuticals Inc realized cash reduction of $ -0.07 per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on ARDS's Valuation
|
|
|
|
|
Aridis Pharmaceuticals Inc realized net loss in trailing twelve months.
Aridis Pharmaceuticals Inc realized cash outflow of $ -0.07per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on ARDS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com